Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
ANAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.21 - $41.31
Previous CloseN/A
Volume154.73K
Average Volume (3M)641.76K
Market Cap
$756.25M
Enterprise Value$820.98M
Total Cash (Recent Filing)$339.94M
Total Debt (Recent Filing)$15.57M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Aug 11, 2025EPS Estimate
-1.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding29,380,495
10 Day Avg. Volume522,707
30 Day Avg. Volume641,762
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.33
Price to Sales (P/S)0.00
P/FCF Ratio-11.80
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue2.82
Enterprise Value/Gross Profit7.42
Enterprise Value/Ebitda-1.85
Forecast
1Y Price Target
$47.63Price Target Upside81.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
AnaptysBio News
See All ANAB News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive results from Ph 2 RENOIR evaluating PD-1 agonist rosnilimab for rheumatoid arthritis included efficacy comparable to JAK inhibitors, deepening of response, and no safety signals relative to placebo.
Efficacy And SafetyANAB's rosnilimab demonstrated strong efficacy and durability across both biologic-naïve and experienced populations in rheumatoid arthritis.
Market PerformanceShares are up 76% year-to-date, as investors see ANAB's Jemperli royalty value as a floor for the stock and incremental data for rosnilimab continues to demonstrate a differentiated efficacy and safety profile in RA.
Bears Say
Competition ConcernsDisappointing UC results for competitor JNJ’s PD-1 agonist JNJ-67484703 raise questions about rosnilimab’s Ph2b UC readout, although JNJ's data in RA appears weaker cross-trial relative to rosnilimab.
Uncertainty In UC TrialsDespite the potential for rosnilimab, questions remain regarding the Ph2b UC readout, especially in light of competitive landscape and JNJ's struggles in this area.
Ownership Overview
43.85% Insiders
21.76% Mutual Funds
0.91% Other Institutional Investors
22.15% Public Companies and Individual Investors
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $12.21 and its highest was $41.31 in the past 12 months.
What is AnaptysBio Inc’s market cap?
AnaptysBio Inc’s market cap is $756.25M.
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Aug 11, 2025 which is in 29 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on May 05, 2025. The company reported -$1.28 earnings per share for the quarter, missing the consensus estimate of -$1.253 by -$0.027.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -1.53.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 29,380,495 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$1.28 in its last earnings report, missing expectations of -$1.253. Following the earnings report the stock price went down -2.943%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Currently, no hedge funds are holding shares in ANAB
AnaptysBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.63 (81.79% Upside)
$47.63 (81.79% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.39%
12-Months-Change
Fundamentals
Return on Equity
-343.83%
Trailing 12-Months
Asset Growth
4.00%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB Stock 12 Month Forecast
Average Price Target
$47.63
▲(81.79%Upside)